Clinical trialsOfficial
ANSM bans direct lab sales of furosemide to pharmacies as shortage seen lasting into 2027
🇫🇷 ANSM · Wed 18 Nov 2026
France's medicines agency is combining imports, extra production, unit dispensing and compounded capsules to protect treatment continuity for patients during furosemide 20 mg and 40 mg supply tensions.
France's medicines agency ANSM said on 18 November 2026 that severe supply tensions affecting furosemide 20 mg and 40 mg medicines are continuing and should last several more months in 2027. It is reinforcing earlier measures and adding new ones to limit the risk of patients losing access to treatment. The agency attributes the persistent difficulties to supply problems at the marketing company Viatris.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Article written by VigiEye from the official source (ANSM). AI-assisted; check the source before acting.
More Clinical trials
All →
Teleflex recalls PICC kits and spring-wire guides over coating detachment risk, Health Canada reports
🇨🇦 Health Canada · Wed 18 Nov 2026
Health Canada: Raz Design recalls shower commode chairs over seats that can break
🇨🇦 Health Canada · Wed 18 Nov 2026
Summit starts Phase III HARMONi-10 of ivonescimab against durvalumab in Stage III NSCLC
🇺🇸 Summit Therapeutics Inc. (SMMT) · Wed 18 Nov 2026
NeOnc deck reports Phase 2a intranasal NEO100 results in recurrent IDH1-mutant glioma
🇺🇸 Neonc Technologies Holdings, Inc. (NTHI) · Wed 18 Nov 2026
Lantern Pharma opens first TNBC trial site, starts HARMONIC Part 2 in Taiwan; CEO resigns
🇺🇸 Lantern Pharma Inc. (LTRN) · Wed 18 Nov 2026
Optimi Health seeks to make psilocybin depression study randomised Phase 2b; MDMA Phase 3 planned
Optimi Health Corp. (OPTH) · Wed 18 Nov 2026